calcium chloride dihydrate + potassium chloride + sodium chloride + sodium lactate: clinical use

Prescribing considerations

• Assess volume status, electrolyte requirements, acid–base balance, renal function and risks of sodium, potassium or calcium retention.
• Use additional caution in cardiac, pulmonary, renal or severe hepatic impairment, pre-eclampsia, acute dehydration, extensive tissue injury, burns, sarcoidosis and a history of calcium renal calculi.
• The calcium content creates compatibility issues with ceftriaxone, citrate-preserved blood and some additives.
• Lactate may not produce the intended alkalinising effect when hepatic lactate metabolism is substantially impaired.
• It is not appropriate for severe potassium deficiency.

Contraindications and cautions

• Product-specific contraindications include extracellular hyperhydration or hypervolaemia, severe renal insufficiency with oliguria or anuria, uncompensated cardiac failure, hyperkalaemia, hypercalcaemia, metabolic alkalosis, severe metabolic acidosis, lactic acidosis or impaired lactate utilisation, ascitic cirrhosis and concomitant digitalis therapy.
• Ceftriaxone with calcium-containing intravenous solutions is contraindicated in newborns aged 28 days or younger, even through separate infusion lines.
• Contraindications differ between selected products; consult the SmPC for the exact preparation.

Monitoring

• Assess fluid balance and watch for oedema or pulmonary congestion.
• Monitor serum electrolytes, particularly sodium and potassium, and acid–base balance.
• Monitor more closely with impaired cardiac, pulmonary, renal or hepatic function or medicines affecting vasopressin, sodium, potassium or calcium.
• Consider blood glucose monitoring in type 2 diabetes because lactate is a gluconeogenic substrate.
• Observe the infusion site for extravasation, phlebitis and infection.

Clinical pharmacology

A balanced crystalloid that expands the extracellular compartment. Its effects reflect its sodium, potassium, calcium and chloride content; lactate undergoes predominantly hepatic oxidation and gluconeogenesis, generating bicarbonate and an alkalinising effect.

Formulation and product differences

• Both selected products are clear intravenous infusion solutions with water for injections and a similar electrolyte–lactate profile.
• Container systems and additive instructions differ. One permits compatible additives after formal assessment and aseptic preparation; the other states that it must not be mixed with other medicines without compatibility studies.
• Check the exact product SmPC before adding medicines, selecting administration equipment or determining storage after preparation.